Table 1.
Summary of datasets used to assess priority ranking performance
| Data set | Source | Database (inputs) | Records from search | Included | Excluded | Comments |
|---|---|---|---|---|---|---|
| PFOA/PFOS and immunotoxicity | NIEHS | PubMed (PMIDs) | 6331 | 95 (1.5 %) | 6236 (98.5 %) | Targeted topica |
| Bisphenol A (BPA) and obesity | NIEHS | PubMed (PMIDs) | 7700 | 111 (1.4 %) | 7589 (98.6 %) | Targeted topic |
| Transgenerational inheritance of health effects | NIEHS | PubMed (PMIDs) | 48,638 | 765 (1.6 %) | 47,873 (98.4 %) | Untargeted topic |
| Fluoride and neurotoxicity in animal models | NIEHS | Multiple (titles + abstracts) | 4479 | 51 (1.1 %) | 4428 (98.9 %) | Targeted topic |
| Neuropathic pain | CAMARADES | Multiple (titles + abstracts) | 29,207 | 5011 (17.2 %) | 24,196 (82.8 %) | Semi-targeted topic |
| Skeletal muscle relaxants | [6] | PubMed (PMIDs) | 1643 | 9 (0.6 %) | 1634 (99.4 %) | Public dataset |
| Opioids | [6] | PubMed (PMIDs) | 1915 | 15 (0.8 %) | 1900 (99.2 %) | Public dataset |
| Antihistamines | [6] | PubMed (PMIDs) | 310 | 16 (5.2 %) | 294 (94.8 %) | Public dataset |
| ADHD | [6] | PubMed (PMIDs) | 851 | 20 (2.4 %) | 831 (97.6 %) | Public dataset |
| Triptans | [6] | PubMed (PMIDs) | 671 | 24 (3.6 %) | 647 (96.4 %) | Public dataset |
| Urinary Incontinence | [6] | PubMed (PMIDs) | 327 | 40 (12.2 %) | 287 (87.8 %) | Public dataset |
| Ace Inhibitors | [6] | PubMed (PMIDs) | 2544 | 41 (1.6 %) | 2503 (98.4 %) | Public dataset |
| Nonsteroidal anti-inflammatory | [6] | PubMed (PMIDs) | 393 | 41 (10.4 %) | 352 (89.6 %) | Public dataset |
| Beta blockers | [6] | PubMed (PMIDs) | 2072 | 42 (2.0 %) | 2030 (98.0 %) | Public dataset |
| Proton pump inhibitors | [6] | PubMed (PMIDs) | 1333 | 51 (3.8 %) | 1282 (96.2 %) | Public dataset |
| Estrogens | [6] | PubMed (PMIDs) | 368 | 80 (21.7 %) | 288 (78.3 %) | Public dataset |
| Statins | [6] | PubMed (PMIDs) | 3465 | 85 (2.5 %) | 3380 (97.5 %) | Public dataset |
| Calcium-channel blockers | [6] | PubMed (PMIDs) | 1218 | 100 (8.2 %) | 1118 (91.8 %) | Public dataset |
| Oral hypoglycemics | [6] | PubMed (PMIDs) | 503 | 136 (27.0 %) | 367 (73.0 %) | Public dataset |
| Atypical antipsychotics | [6] | PubMed (PMIDs) | 1120 | 146 (13.0 %) | 974 (87.0 %) | Public dataset |
aTargeted topics refers to examples where a specific exposure and health outcome were identified (e.g., bisphenol A and obesity); for untargeted topics, one or both of these parameters were not defined, e.g., the topic transgenerational inheritance of health effect focused on a particular study design and was not restricted to a specific type of exposure or health outcome